SCHEMBL7607672

SCHEMBL7607672

CCC(C(=O)O)c1ncccc1P(=O)(O)Cc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
ALPG P10696 1/20 0.33
PTK2B Q14289 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
FDPS P14324 1/20 0.33
HIF1A Q16665 1/20 0.33
THRB P10828 1/20 0.33
P4HTM Q9NXG6 1/20 0.33
ACE P12821 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609311 0.85 KMT2A (0.36) SMN1; SMN2ALPGPTK2BPOLBKMT2A
SCHEMBL7610494 0.77 GAA (0.38) LMNAALDH1A1SMN1; SMN2GAAKDM4E
SCHEMBL7610507 0.73 AKR1C3 (0.39)
SCHEMBL7609491 0.73 POLB (0.34) POLBFDPS
SCHEMBL7608740 0.73 POLB (0.34) ALDH1A1SMN1; SMN2L3MBTL1POLB
SCHEMBL7613680 0.73 ATM (0.38) LMNASMN1; SMN2KDM4EKMT2A
SCHEMBL7614101 0.72 L3MBTL1 (0.41) LMNAALDH1A1SMN1; SMN2GAAL3MBTL1
SCHEMBL7604654 0.72 HTT (0.37) LMNAALDH1A1SMN1; SMN2GAAL3MBTL1
SCHEMBL895915 0.72 SMN1; SMN2 (0.41) LMNAALDH1A1SMN1; SMN2GAAHTT
SCHEMBL895866 0.71 KCNQ2 (0.42) LMNAALDH1A1SMN1; SMN2HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002515040-A 2002-05-21 JP claimed
JP-2002514160-A 2002-05-14 JP claimed
JP-2002514184-A 2002-05-14 JP claimed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP claimed
EP-0954295-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-11-10 EP claimed
EP-0936914-A1 HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-08-25 EP claimed
EP-0936914-A4 1999-08-25 EP claimed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO claimed
WO-1997048400-A1 HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-12-24 WO claimed
WO-1997048409-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-12-24 WO claimed
EP-1044206-A1 PRODRUGS OF NAALADASE INHIBITORS Guildford Pharmaceuticals Inc. (US) 2000-10-18 EP disclosed
WO-1999033849-A1 PRODRUGS OF NAALADASE INHIBITORS GUILDFORD PHARMACEUTICALS INC. (US) 1999-07-08 WO disclosed